Field Trip has now completed the dosing of the first patients in its Phase 1 clinical study: A double-blind, randomised, placebo-controlled study to investigate the safety,...
InsightAce Analytic has projected that the global psychedelic therapeutics market, valued at US$3.61bn in 2021, is expected to reach US$8.31bn (~£6.92bn) by 2028.
PsiloTec Health Solutions Inc.,
MAPS’ Psychedelics Fundamentals online education curriculum is aiming to introduce learners to the most important aspects of psychedelic history, research, uses and harm reduction.
Enveric Biosciences has made advancements with its drug discovery and development progress targeting mental health indications and intellectual property (IP).
Origin Therapeutics has completed an investment in Clairvoyant Therapeutics which will now proceed with a Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use...
Clinilabs Drug Development Corporation has begun enrolment in a Phase 1/2a clinical trial of Cybin’s CYB003 for the treatment of major depressive disorder (MDD).
Algernon Pharmaceuticals is working to complete an intravenous formulation (IVF) that will be used in its Phase 1 DMT study investigating the compound’s efficacy as a...
Filament Health has confirmed it has begun dosing in the first FDA-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.
A novel compound similar in structure to the psychedelic drug ibogaine, but which has no hallucinogenic effects, has been found to rapidly reverse the effects of...
The hallucinogenic effect of psychedelics may hold much healing potential, but researchers believe that these compounds could be beneficial for brain disorders without hallucinations.
The UK’s national innovation agency – Innovate UK – has provided funding to Awakn Life Sciences to help bring its ketamine-assisted therapy to alcohol use disorder...
